Page 49 - Read Online

Page 1000 Juhlin. Cancer Drug Resist 2020;3:992-1000 I http://dx.doi.org/10.20517/cdr.2020.66

chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
38. Martin SA, McCabe N, Mullarkey M, et al. DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch
repair proteins MSH2 or MLH1. Cancer Cell 2010;17:235-48.
39. Hewish M, Martin SA, Elliott R, et al. Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour
cells by enhancing levels of intracellular oxidative stress. Br J Cancer 2013;108:983-92.
40. Martin SA, McCarthy A, Barber LJ, et al. Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with
defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 2009;1:323-37.
41. Revannasiddaiah S, Madabhavi I, Bodh A, Thakur P, Sharma M. Metronomic chemotherapy in anaplastic thyroid carcinoma: a potentially
feasible alternative to therapeutic nihilism. Indian J Palliat Care 2015;21:245-9.
42. Tallroth E, Wallin G, Lundell G, Löwhagen T, Einhorn J. Multimodality treatment in anaplastic giant cell thyroid carcinoma. Cancer
1987;60:1428-31.
43. Ferrás C, Oude Vrielink JAF, Verspuy JWA, et al. Abrogation of microsatellite-instable tumors using a highly selective suicide gene/
prodrug combination. Mol Ther 2009;17:1373-80.
44. Begum R, Martin SA. Targeting mismatch repair defects: a novel strategy for personalized cancer treatment. DNA Repair (Amst)
2016;38:135-9.